Friday, March 18, 2011

Boniva Side Effects

It is important to remember that all drugs may cause certain reactions. Boniva can also cause side effects in some patients. Boniva, or ibandronate sodium, is manufactured by Roche Therapeutics Inc and Genentech. It is approved by the FDA as a once-monthly oral treatment of postmenopausal osteoporosis symptoms in women. The one tablet per month treatment must be prescribed by your doctor.

It has been estimated that as many as 44 million Americans that are over the age of 50 years old are affected with or at risk of developing osteoporosis. Once-monthly Boniva may help to keep people from developing this bone disease and condition, and also may help with the symptoms of those who have postmenapausal osteoporosis. Basically, osteoporosis is a bone disease that can cause a person's bones to become weak and brittle. It can also be the cause of low bone mass. The bone disease can cause a lot of pain and discomfort.

Boniva  Side Effects:

All drugs and medications have the potential to cause interactions, but does not mean that all people will develop any side effects. While not a complete list, some of the common side effects of this once-monthly table tablet medication can cause include the following list of adverse effects.

Common reactions:
• headache
• heartburn
• pain in the arms and legs
• diarrhea
• tiredness
• dizziness
• nausea
• muscle aches

Some potential severe Boniva side effects:
• severe allergic reactions
• facial swelling
• eye pain
• chest tightness
• severe bone pain
• severe stomach pain

Contact your doctor immediately if you experience any of these or other severe side effects. Discuss all risks, concerns and potential reactions with your physician before taking Boniva.

Review this bone disease and concerns with your doctor.

Prescription Savings and Coupon Offer:
www.MyBoniva.com Free Boniva Offer Review  

Resources:
www.boniva.com/about_boniva/side_effects.aspx    
www.drugs.com/boniva_150.html    
www.medicinenet.com/ibandronate/article.htm  

No comments: